ATNX लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (25 May 2023 @ 01:30):

Stats
आज की मात्रा	1.75M
औसत मात्रा	263 314
बाजार मूल्य	2.33M
EPS	$0 ( 2024-03-18 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0194
ATR14	$0.141 (69.42%)

Insider Trading

Date	Person	Action	Amount	type
2023-05-05	Lau Johnson Yiu Nam	Buy	8 382	Common Stock
2023-05-05	Kwan Rudolf	Buy	3 603	Common Stock
2023-05-05	Cook Timothy Devere	Buy	368	Common Stock
2023-04-21	Wu Jinn	Buy	6 513	Common Stock
2023-04-21	Vierling John	Buy	6 513	Common Stock

INSIDER POWER
94.87
Last 100 transactions
Buy: 1 577 577 \| Sell: 76 746

मात्रा सहसंबंध

लंबा: -0.35 (neutral)

छोटा: -0.81 (strong negative)

Signal:(17.17) Be Aware. Possible trading coming up! (swing)

Athenex Inc सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
RUBY	0.962
PETS	0.952
IMKTA	0.951
MRBK	0.949
SSTI	0.948
VERU	0.948
CYXT	0.946
AGIL	0.946
CUE	0.945
GOVX	0.944

10 सबसे अधिक नकारात्मक सहसंबंध
ISRG	-0.954
HBIO	-0.95
LMRKO	-0.948
TYHT	-0.946
VRTX	-0.945
ICVX	-0.945
CREX	-0.943
LMRKP	-0.942
ALXN	-0.942
BRAC	-0.942

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Athenex Inc सहसंबंध - मुद्रा/वस्त्र

-0.81
( strong negative )

-0.76
( moderate negative )

0.27
( neutral )

-0.80
( moderate negative )

-0.58
( weak negative )

0.70
( moderate )

Athenex Inc वित्तीय

Annual	2022
राजस्व:	$102.82M
सकल लाभ:	$26.70M (25.97 %)
EPS:	$-15.13

FY	2022
राजस्व:	$102.82M
सकल लाभ:	$26.70M (25.97 %)
EPS:	$-15.13

FY	2021
राजस्व:	$120.18M
सकल लाभ:	$37.78M (31.43 %)
EPS:	$-1.920

FY	2020
राजस्व:	$144.39M
सकल लाभ:	$49.04M (33.96 %)
EPS:	$-1.720

Financial Reports:

No articles found.

Athenex Inc

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.